Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).

1 finding from 1 review

All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome

It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).

1 finding from 1 review